Pfizer Inc.(NYSE:PFE) Bivalent rLP2086 treatment has received a breakthrough designation from the FDA for preventing Meningococcal B Disease in sufferers aged 10-25.Pfizer is conducting Phase II and III trials for rLP2086 in studies that involve over 20,000 participants, of which 14,000 will receive the vaccine.Meningococcal disease is caused by a bacterium called Neisseria meningitidis and can lead to meningitis and widespread blood infection (sepsis), as well as death or long-term disabilities such as brain damage and hearing loss.Of the five main meningococcal serogroups, serogroup B is the only one for which there is no FDA approved broadly-protective vaccine Pfizer Inc. (NYSE:PFE) shares after opening at $32.33 moved to $32.49 on last trade day and at the end of the day closed at $32.18. Company price to sales ratio in past twelve months was calculated as 4.25 and price to cash ratio as 6.67. Pfizer Inc. (NYSE:PFE) showed a positive weekly performance of 3.04%.
Gilead Sciences (NASDAQ:GILD)‘s stock had its “buy” rating restated by equities research analysts at Deutsche Bank in a research note issued to investors on Friday, American Banking News reports. Gilead Sciences, Inc. (NASDAQ:GILD) shares fell -4.57% in last trading session and ended the day on $72.07. GILD return on equity ratio is recorded as 28.30% and its return on assets is 13.70%. Gilead Sciences, Inc. (NASDAQ:GILD) yearly performance is 61.81%.
Johnson & Johnson (NYSE:JNJ)‘s stock had its “buy” rating restated by equities researchers at Jefferies Group in a research report issued on Wednesday, ARN reports. They currently have a $105.00 target price on the stock. Jefferies Group’s price target points to a potential upside of 11.56% from the company’s current price. Johnson & Johnson (NYSE:JNJ) shares moved up 1.92% in last trading session and was closed at $95.93, while trading in range of $93.88-$95.93. Johnson & Johnson (NYSE:JNJ) year to date performance is 5.49%.
Equities research analysts at Jefferies Group increased their price target on shares of Merck & Co. (NYSE:MRK) to $57.00 in a research note issued to investors on Wednesday, ARN reports. Jefferies Group’s price objective indicates a potential upside of 2.54% from the company’s current price.Merck & Co., Inc. (NYSE:MRK) weekly performance is -1.87%. On last trading day company shares ended up $54.66. Merck & Co., Inc. (NYSE:MRK) distance from 50-day simple moving average is 1.05%. Analysts mean target price for the company is $56.44.
Leave a Reply